| Official Full Name |
Recombinant Human Interleukin-36 Receptor Antagonist Protein (rHuIL-36RA) |
| Squence |
 |
| Amino Acid Sequence |
VLSGALCFRM KDSALKVLYL HNNQLLAGGL HAGKVIKGEE ISVVPNRWLD ASLSPVILGV QGGSQCLSCG VGQEPTLTLE PVNIMELYLG AKESKSFTFY RRDMGLTSSF ESAAYPGWFL CTVPEADQPV RLTQLPENGG WNAPITDFYF QQCD |
| 别名 |
IL-1RP3, IL-1HY1, IL-1 delta, IL-1F5, IL-1ra homolog 1, IL-1L1 |
| Accession Number |
Q9UBH0 |
| GeneID |
26525 |
| Summary |
Interleukin-36 receptor antagonist (IL-36RA) is a secreted protein which belongs to the interleukin 1 cytokine family (IL-1 family) and it is predominantly expressed in keratinocytes but not in fibroblasts, endothelial cells or melanocytes. IL-36RA has been reported to antagonize the biological activity of IL-36alpha (IL-1F6), IL-36β (IL-1F8), and IL-36gamma (IL-1F9). Furthermore, it could constitute part of an independent signaling system analogous to interleukin-1 alpha (IL-1A), beta (IL-1B) receptor agonist and interleukin-1 receptor type I (IL-1R1). In addition, The receptor for IL-36RA has not been positively identified. Indirect evidence suggests it is IL-1Rrp2. Recombinant human IL-36 RA contains 154 amino acid residues and it shares 91 % a.a. sequence identity with murine IL-36RA. |
| Source |
Escherichia coli. |
| 分子量 |
Approximately 16.8 kDa, a single non-glycosylated polypeptide chain containing 154 amino acids. |
| Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by inhibiting IL-36 beta induced IL-8 secretion by human preadipocytes is less than 1.0 ug/ml, corresponding to a specific activity of > 1000 IU/mg in the presence of 20 ng/ml of recombinant human IL-36 beta. |
| Appearance |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation |
Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin |
Less than 1 EU/ug of rHuIL-36RA as determined by LAL method. |
| Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| References |
|
| SDS-PAGE |
 |
| Safety Data Sheet (SDS) Download |
Click to download |
| Technical Data Sheet (TDS) Download |
Click to download |
